ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

NMRA Neumora Therapeutics Inc

9.63
-0.02 (-0.21%)
Last Updated: 10:27:48
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Neumora Therapeutics Inc NMRA NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.02 -0.21% 9.63 10:27:48
Open Price Low Price High Price Close Price Previous Close
9.70 9.44 9.73 9.65
more quote information »

Recent News

Date Time Source Heading
5/14/202406:00GLOBENeumora Therapeutics Announces Initiation of Phase 2 Study..
5/07/202415:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
5/07/202406:15EDGAR2Form 8-K - Current report
5/07/202406:00GLOBENeumora Therapeutics Reports First Quarter 2024 Financial..
5/06/202406:00GLOBENeumora Therapeutics to Participate in Upcoming Conferences..
4/15/202405:30GLOBENeumora Therapeutics Announces Clinical Hold of Phase 1..
3/13/202406:00GLOBENeumora Therapeutics to Participate at Stifel 2024 Virtual..
3/07/202415:34EDGAR2Form S-8 - Securities to be offered to employees in employee..
3/07/202406:08EDGAR2Form 8-K - Current report
3/07/202406:00GLOBENeumora Therapeutics Reports Fourth Quarter and Full Year..
2/16/202415:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/16/202415:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/16/202415:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/16/202415:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/22/202406:00GLOBENeumora Therapeutics Appoints Kaya Pai Panandiker as Chief..
1/08/202407:32EDGAR2Form 8-K - Current report
1/02/202406:00GLOBENeumora Therapeutics to Present at 42nd Annual J.P. Morgan..
12/15/202316:06EDGAR2Form SC 13D/A - General statement of acquisition of..
12/12/202306:00GLOBENeumora Therapeutics Appoints Jason Duncan as Chief Legal..
11/28/202315:21EDGAR2Form 8-K - Current report
11/27/202306:00GLOBENeumora Therapeutics Announces NMRA-266 IND Clearance and..
11/01/202315:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/01/202315:01EDGAR2Form 8-K - Current report
11/01/202306:00GLOBENeumora Therapeutics Reports Third Quarter 2023 Financial..
10/30/202306:00GLOBENeumora Therapeutics to Participate in Upcoming Conferences..
10/10/202306:00GLOBENeumora Therapeutics Announces Appointment of Robert Lenz,..
9/14/202319:49GLOBENeumora Therapeutics Announces Pricing of Initial Public..

Your Recent History

Delayed Upgrade Clock